Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy

References

• Bray F, Jemal A, Grey N, et al. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol. 2012;13(8):790–801.
   PubMed Web of Science ®Google Scholar
• Chabner BA, Roberts TG Jr. Timeline: chemotherapy and the war on cancer. Nat Rev Cancer. 2005;5(1):65–72.
   PubMed Web of Science ®Google Scholar
• Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007;7(3):192–201.
   PubMed Web of Science ®Google Scholar
• Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7(8):573–584.
   PubMed Web of Science ®Google Scholar
• Coffey JC, Wang JH, Smith MJ, et al. Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol. 2003;4(12):760–768.
   PubMed Web of Science ®Google Scholar
• Liu C, Zhao G, Liu J, et al. Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel. J Control Release. 2009;140(3):277–283.
   PubMed Web of Science ®Google Scholar
• Tekade RK, Dutta T, Tyagi A, et al. Surface-engineered dendrimers for dual drug delivery: a receptor up-regulation and enhanced cancer targeting strategy. J Drug Target. 2008;16(10):758–772.
   PubMed Web of Science ®Google Scholar
• Malmstrom P-U, Rintala E, Wahlqvist R, et al. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial 1. J Urol. 1996;155(6):1903–1906.
   PubMed Web of Science ®Google Scholar
• Steinberg JL, Yeo W, Zhong S, et al. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role. J Med Virol. 2000;60(3):249–255.
   PubMed Web of Science ®Google Scholar
• Chabner BA, Roberts TG. Chemotherapy and the war on cancer. Nat Rev Cancer. 2005;5(1):65–72.
   PubMed Web of Science ®Google Scholar
• Hu C-MJ, Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol. 2012;83(8):1104–1111.
   PubMed Web of Science ®Google Scholar
• Song S, Wientjes MG, Walsh C, et al. Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases. Cancer Res. 2001;61(16):6145–6150.
   PubMed Web of Science ®Google Scholar
• Lehár J, Krueger AS, Avery W, et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol. 2009;27(7):659–666.
   PubMed Web of Science ®Google Scholar
• Mu L, Feng SS. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J Control Release. 2003;86(1):33–48.
   PubMed Web of Science ®Google Scholar
• Primeau AJ, Rendon A, Hedley D, et al. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res. 2005;11(24):8782–8788.
   PubMed Web of Science ®Google Scholar
• Creixell M, Peppas NA. Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. Nano Today. 2012;7(4):367–379.
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751–760.
   PubMed Web of Science ®Google Scholar
• Hu Q, Sun W, Wang C, et al. Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv Drug Deliv Rev. 2016;98:19–34.
   PubMed Web of Science ®Google Scholar
• Nussbaumer S, Bonnabry P, Veuthey J-L, et al. Analysis of anticancer drugs: a review. Talanta. 2011;85(5):2265–2289.
   PubMed Web of Science ®Google Scholar
• Woodcock J, Griffin JP, Behrman RE. Development of novel combination therapies. New England J Med. 2011;364(11):985–987.
   PubMed Web of Science ®Google Scholar
• Jia J, Zhu F, Ma X, et al. Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov. 2009;8(2):111–128.
   PubMed Web of Science ®Google Scholar
• Mayer LD, Janoff AS. Optimizing combination chemotherapy by controlling drug ratios. Mol Interv. 2007;7(4):216–223.
   PubMedGoogle Scholar
• Zimmermann GR, Lehár J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007;12(1–2):34–42.
   PubMed Web of Science ®Google Scholar
• Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol. 2012;30(7):679–692.
   PubMed Web of Science ®Google Scholar
• Kolishetti N, Dhar S, Valencia PM, et al. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad of Sci. 2010;107(42):17939–17944.
   PubMed Web of Science ®Google Scholar
• Xiao B, Si X, Han MK, et al. Co-delivery of camptothecin and curcumin by cationic polymeric nanoparticles for synergistic colon cancer combination chemotherapy. J Mater Chem B. 2015;3(39):7724–7733.
   PubMed Web of Science ®Google Scholar
• Hu C-MJ, Aryal S, Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther Deliv. 2010;1(2):323–334.
   PubMedGoogle Scholar
• Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature. 2009;457(7228):426–433.
   PubMed Web of Science ®Google Scholar
• Jinek M, Doudna JA. A three-dimensional view of the molecular machinery of RNA interference. Nature. 2009;457(7228):405–412.
   PubMed Web of Science ®Google Scholar
• Daka A, Peer D. RNAi-based nanomedicines for targeted personalized therapy. Adv Drug Deliv Rev. 2012;64(13):1508–1521.
   PubMed Web of Science ®Google Scholar
• Xuan B, Qian Z, Tan C, et al. esiRNAs purified with chromatography suppress homologous gene expression with high efficiency and specificity. Mol Biotechnol. 2005;31(3):203–209.
   PubMed Web of Science ®Google Scholar
• De Fougerolles A, Vornlocher H-P, Maraganore J, et al. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov. 2007;6(6):443–453.
   PubMed Web of Science ®Google Scholar
• Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet. 2007;8(3):173–184.
   PubMed Web of Science ®Google Scholar
• Xu C-F, Zhang H-B, Sun C-Y, et al. Tumor acidity-sensitive linkage-bridged block copolymer for therapeutic siRNA delivery. J Biomaterials. 2016;88:48–59.
   PubMed Web of Science ®Google Scholar
• Lee S-Y, Yang C-Y, Peng C-L, et al. A theranostic micelleplex co-delivering SN-38 and VEGF siRNA for colorectal cancer therapy. Biomaterials. 2016;86:92–105.
   PubMed Web of Science ®Google Scholar
• Yin T, Wang L, Yin L, et al. Co-delivery of hydrophobic paclitaxel and hydrophilic AURKA specific siRNA by redox-sensitive micelles for effective treatment of breast cancer. Biomaterials. 2015;61:10–25.
   PubMed Web of Science ®Google Scholar
• Whitehurst AW, Bodemann BO, Cardenas J, et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature. 2007;446(7137):815–819.
   PubMed Web of Science ®Google Scholar
• Yang -Z-Z, Li J-Q, Wang -Z-Z, et al. Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials. 2014;35(19):5226–5239.
   PubMed Web of Science ®Google Scholar
• Yin T, Wang P, Li J, et al. Tumor-penetrating codelivery of siRNA and paclitaxel with ultrasound-responsive nanobubbles hetero-assembled from polymeric micelles and liposomes. Biomaterials. 2014;35(22):5932–5943.
   PubMed Web of Science ®Google Scholar
• Beh CW, Seow WY, Wang Y, et al. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug. Biomacromolecules. 2009;10(1):41–48.
   PubMed Web of Science ®Google Scholar
• Chen AM, Zhang M, Wei D, et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small. 2009;5(23):2673–2677.
   PubMed Web of Science ®Google Scholar
• Zheng C, Zheng M, Gong P, et al. Polypeptide cationic micelles mediated co-delivery of docetaxel and siRNA for synergistic tumor therapy. Biomaterials. 2013;34(13):3431–3438.
   PubMed Web of Science ®Google Scholar
• Sun T-M, Du J-Z, Yao Y-D, et al. Simultaneous delivery of siRNA and paclitaxel via a “two-in-one” micelleplex promotes synergistic tumor suppression. ACS Nano. 2011;5(2):1483–1494.
   PubMed Web of Science ®Google Scholar
• Xiong X-B, Lavasanifar A. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. ACS Nano. 2011;5(6):5202–5213.
   PubMed Web of Science ®Google Scholar
• Zhang L, Gu F, Chan J, et al. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharm Ther. 2008;83(5):761–769.
   PubMed Web of Science ®Google Scholar
• Xiao B, Han MK, Viennois E, et al. Hyaluronic acid-functionalized polymeric nanoparticles for colon cancer-targeted combination chemotherapy. Nanoscale. 2015;7(42):17745–17755.
   PubMed Web of Science ®Google Scholar
• Gao J, Chen H, Yu Y, et al. Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA. Biomaterials. 2013;34(38):10084–10098.
   PubMed Web of Science ®Google Scholar
• Biswas S, Deshpande PP, Navarro G, et al. Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery. Biomaterials. 2013;34(4):1289–1301.
   PubMed Web of Science ®Google Scholar
• Zeng S, Xiong MP. Trilayer micelles for combination delivery of rapamycin and siRNA targeting Y-box binding protein-1 (siYB-1). Biomaterials. 2013;34(28):6882–6892.
   PubMed Web of Science ®Google Scholar
• Patil YB, Swaminathan SK, Sadhukha T, et al. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials. 2010;31(2):358–365.
   PubMed Web of Science ®Google Scholar
• Meng H, Mai WX, Zhang H, et al. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano. 2013;7(2):994–1005.
   PubMed Web of Science ®Google Scholar
• Barenholz Y. Doxil®--the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117–134.
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145–160.
   PubMed Web of Science ®Google Scholar
• Itaka K, Kataoka K. Progress and prospects of polyplex nanomicelles for plasmid DNA delivery. Curr Gene Ther. 2011;11(6):457–465.
   PubMed Web of Science ®Google Scholar
• Matsumura Y. Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. Adv Drug Deliv Rev. 2011;63(3):184–192.
   PubMed Web of Science ®Google Scholar
• Crooks RM, Zhao M, Sun L, et al. Dendrimer-encapsulated metal nanoparticles: synthesis, characterization, and applications to catalysis. Acc Chem Res. 2001;34(3):181–190.
   PubMed Web of Science ®Google Scholar
• Dwivedi P, Kumar Tekade R, Kumar Jain N. Nanoparticulate carrier mediated intranasal delivery of insulin for the restoration of memory signaling in Alzheimer’s disease. Curr Nanosci. 2013;9(1):46–55.
   Web of Science ®Google Scholar
• Cheng Y, Zhao L, Li Y, et al. Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives. Chem Soc Rev. 2011;40(5):2673–2703.
   PubMed Web of Science ®Google Scholar
• Wang C-Z, Fu Y-C, Jian S-C, et al. Synthesis and characterization of cationic polymeric nanoparticles as simvastatin carriers for enhancing the osteogenesis of bone marrow mesenchymal stem cells. J Colloid Interface Sci. 2014;432:190–199.
   PubMed Web of Science ®Google Scholar
• Xiao B, Zhang M, Viennois E, et al. Inhibition of MDR1 gene expression and enhancing cellular uptake for effective colon cancer treatment using dual-surface-functionalized nanoparticles. Biomaterials. 2015;48:147–160.
   PubMed Web of Science ®Google Scholar
• Panyam J, Sahoo SK, Prabha S, et al. Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(d,l-lactide-co-glycolide) nanoparticles. Int J Pharm. 2003;262(1–2):1–11.
   PubMed Web of Science ®Google Scholar
• Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2012;64:61–71.
   Web of Science ®Google Scholar
• Kamaly N, Yameen B, Wu J, et al. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem Rev. 2016;116(4):2602–2663.
   PubMed Web of Science ®Google Scholar
• Ford Versypt AN, Pack DW, Braatz RD. Mathematical modeling of drug delivery from autocatalytically degradable PLGA microspheres – a review. J Control Release. 2013;165(1):29–37.
   PubMed Web of Science ®Google Scholar
• Kim H-O, Kim E, An Y, et al. A biodegradable polymersome containing Bcl‐xL siRNA and doxorubicin as a dual delivery vehicle for a synergistic anticancer effect. Macromol Biosci. 2013;13(6):745–754.
   PubMed Web of Science ®Google Scholar
• Xiao B, Wan Y, Wang X, et al. Synthesis and characterization of N-(2-hydroxy)propyl-3-trimethyl ammonium chitosan chloride for potential application in gene delivery. Colloids Surf B Biointerfaces. 2012;91:168–174.
   PubMed Web of Science ®Google Scholar
• Xiao B, Wang X, Qiu Z, et al. A dual-functionally modified chitosan derivative for efficient liver-targeted gene delivery. J Biomed Mater Res A. 2013;101(7):1888–1897.
   PubMed Web of Science ®Google Scholar
• Wei W, Lv -P-P, Chen X-M, et al. Codelivery of mTERT siRNA and paclitaxel by chitosan-based nanoparticles promoted synergistic tumor suppression. Biomaterials. 2013;34(15):3912–3923.
   PubMed Web of Science ®Google Scholar
• Li G, Song S, Zhang T, et al. pH-sensitive polyelectrolyte complex micelles assembled from CS-g-PNIPAM and ALG-g-P(NIPAM-co-NVP) for drug delivery. Int J Biol Macromol. 2013;62:203–210.
   PubMed Web of Science ®Google Scholar
• Zhang C-G, Zhu W-J, Liu Y, et al. Novel polymer micelle mediated co-delivery of doxorubicin and P-glycoprotein siRNA for reversal of multidrug resistance and synergistic tumor therapy. Sci Rep. 2016;6:23859.
   PubMed Web of Science ®Google Scholar
• Lee E, Oh C, Kim I-S, et al. Co-delivery of chemosensitizing siRNA and an anticancer agent via multiple monocomplexation-induced hydrophobic association. J Control Release. 2015;210:105–114.
   PubMed Web of Science ®Google Scholar
• Judge A, MacLachlan I. Overcoming the innate immune response to small interfering RNA. Hum Gene Ther. 2008;19(2):111–124.
   PubMed Web of Science ®Google Scholar
• Shi J, Votruba AR, Farokhzad OC, et al. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett. 2010;10(9):3223–3230.
   PubMed Web of Science ®Google Scholar
• Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991–1003.
   PubMed Web of Science ®Google Scholar